Company intelligence / Profile preview

China Nuokang Bio-Pharmaceutical

Penglai, Shandong, China

Ownership: Private
Development stage: Other

Overview

Company commercially sells Baquting (leading hemocoagulase for bleeding control, 94% of revenue in 2009), Aiduo, Aiwen, and 11 others; pipeline includes 4 candidates with Phase I completed for Agkistrodon acutus hemocoagulase

Therapeutic areas: HematologyCardiovascularNephrology
Modalities: Small moleculeProteinEnzyme
Industry: Biotech

Partnerships

Jilin Yuhua Pharmaceutical Co., Ltd. (exclusive distribution for Kaitong)Shenyang Guangda Pharmaceutical Co., Ltd. (manufacturing for Aiduo/Aiwen)Shenyang Wanjia Biotechnology Research InstituteChinese Academy of Sciences Kunming Animal Research Institute (co-development)

Beyond the preview

Go deeper on China Nuokang Bio-Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Nuokang Bio-Pharmaceutical.

Explore the full profile